Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 5,560 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Active, not recruiting Not applicable Interventional

High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease

NCT04042922
View directory record Official record
Conditions
Alzheimer Disease
Interventions
GENUS device (Active Settings), GENUS device (Sham Settings)
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
50 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 17, 2026, 9:45 AM EDT
Terminated Phase 2 Interventional Results available

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

NCT00895895
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
37
States / cities
Phoenix, Arizona • Costa Mesa, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 17, 2026, 9:45 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
VHB937, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment

NCT04206670
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions
In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 17, 2026, 9:45 AM EDT
Not listed Phase 1 Interventional

Promoting Physical Activity Engagement for People With Early-stage Cerebellar Ataxia

NCT05157802
View directory record Official record
Conditions
Cerebellar Ataxia
Interventions
Physical activity coaching
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

NCT04102501
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
RT001, Placebo
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
12 Years to 50 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Long Beach, California • Los Angeles, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Phase 2 Interventional Results available

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

NCT01370811
View directory record Official record
Conditions
Sialorrhoea
Interventions
oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C, oxybutynin and clonidine oral solution treatment D
Drug
Lead sponsor
Orient Pharma Co., Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bingham Farms, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Phase 2 Interventional Results available

LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia

NCT00759863
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Lifezig
Behavioral
Lead sponsor
Photozig, Inc.
Industry
Eligibility
21 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Moffett Field, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 17, 2026, 9:45 AM EDT
Enrolling by invitation No phase listed Observational

Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1

NCT05238909
View directory record Official record
Conditions
Neurofibromatosis 1, NF1, Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491932
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders, Anti-Dyskinesia Agents
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Englewood, Colorado • Kansas City, Kansas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

NCT03033498
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
45 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Glendale, California • Orlando, Florida • Grayslake, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 17, 2026, 9:45 AM EDT
Terminated No phase listed Observational

Imaging a Cholinergic Biomarker of Cognition in Parkinson's Disease

NCT05034263
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
50 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 17, 2026, 9:45 AM EDT
Recruiting Not applicable Interventional

Connect-Home: Alzheimer's Disease and Related Dementias

NCT06840587
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Connect-Home ADRD
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
19 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Not applicable Interventional

REmote Assessment and Dynamic Response Intervention

NCT04542109
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Relationship, Marital, Caregiver Stress Syndrome
Interventions
READyR A, READyR B
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
62 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

NCT05581823
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tavapadon, Carbamazepine
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Results available

Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

NCT05615220
View directory record Official record
Conditions
Tourette Disorder
Interventions
Ecopipam Hydrochloride
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
56
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 9:45 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

NCT05328908
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Nivolumab-relatlimab FDC, Regorafenib, TAS-102
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 9:45 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

NCT04924608
View directory record Official record
Conditions
Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Interventions
Selumetinib, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Gainesville, Florida • Rockville, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 9:45 AM EDT
Terminated Phase 2Phase 3 Interventional

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

NCT05116813
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Interventions
Dipraglurant
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Augusta, Georgia • Kansas City, Kansas • New Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Phase 2 Interventional Results available

Image Parkinson's Disease Progression Study

NCT02789020
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo, Magnetic Resonance Imaging, functional Magnetic Resonance Imaging, Physical Function Performance Test
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 77 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 17, 2026, 9:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Barriers to Mental Healthcare Utilization in Parkinson's Disease

NCT01167608
View directory record Official record
Conditions
Parkinson's Disease, Depression, Anxiety
Interventions
No Intervention. This is a cross-sectional survey study.
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
883 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

UB-312 in Patients With Synucleinopathies

NCT05634876
View directory record Official record
Conditions
Multiple System Atrophy, Parkinson Disease
Interventions
UB-312 Injection, Placebo Injection
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 17, 2026, 9:45 AM EDT
Completed Phase 4 Interventional Results available

The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

NCT00988117
View directory record Official record
Conditions
Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
Interventions
Rivastigmine Patch 9.5 cm2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 17, 2026, 9:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Postural Instability in Progressive Supranuclear Palsy

NCT01563276
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Parkinson's Disease
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 17, 2026, 9:45 AM EDT